Abbott Scientists Present a New Approach for Treating Attention-Deficit Hyperactivit...(pressure andwere significantly more effe...)

Date:5/7/2008

pressure and were significantly more effective than placebo in the treatment of adults with ADHD. ABT-089 also demonstrated efficacy on secondary endpoints such as the Adult ADHD Investigator Symptom Report Scale (AISRS) and the self-reported ratings on the Conners' Adult ADHD Rating Scale (CAARS-self).

Moreover, data measured by the Adult ADHD Quality of Live (AAQoL) instrument and the Work Productivity and Activity Impairment (WPAI) scale demonstrated that treatment with ABT-089 appears to significantly improve quality of life and work effectiveness. Using the WPAI scale, subjects reported improvements in work productivity (17 percent) and work effectiveness (14.2 percent), as well as a reduction in absenteeism (6.7 percent).

The most common adverse events observed were headache, insomnia and upper respiratory infection.

Abbott presentations during APA Annual Meeting

New Research Poster Sessions 6, May 7, noon - 2pm ET

* Efficacy and Safety of ABT-089 in Adults with ADHD

* Patient Reported Overall Clinical Improvement Associated with ABT-089 in

Adult ADHD

* Clinical Validity of Adult ADHD Quality of Life (AAQoL) Scale Evaluated

in an Adult ADHD Clinical Trial

* Quality of Life and Work Productivity Improvements Associated with

ABT-089 in Adults with ADHD

* Effects of ABT-089 on Heart Rate and Blood Pressure in Adults

Abbott Neuroscience Portfolio

Building on the company's strong scientific foundation in neuroscience and pain, Abbott has significant research and development efforts underway to investigate new therapeutic approaches to cognitive disorders, such as ADHD, Alzheimer's disease and schizophrenia. Abbott also is investigating new therapies for nociceptive pain conditions such as osteoarthritis and cancer pain, as well as neuropathic pain conditions such as diabetic neuropathy. Abbott scientists have been among the leaders in advancing the understand
'/>"/>

SOURCE Abbott Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Abbott Named One of the Best Places to Launch a Career by BusinessWeek
2. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
3. Abbott Scientists Create One Molecule With Two Antibody Functions
4. Abbott Named to Science Magazines List of Top Employers in the Biotech and Pharmaceutical Industry
5. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
6. Abbott Declares 336th Consecutive Quarterly Dividend
7. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
8. Abbott to Present at JP Morgan Healthcare Conference
9. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
10. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
11. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management